Clinical trial · Interventional
Daptomycin or Vancomycin in Treating Bacteria in the Blood in Patients With Neutropenia Caused By Chemotherapy
An Open-Label, Pilot Study of Daptomycin vs. Vancomycin for Treatment of Gram-Positive Bacteremia in Neutropenic Cancer Patients
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Antibiotics, such as daptomycin and vancomycin, may be effective in treating bacteria in the blood. It is not yet known whether daptomycin is more effective than vancomycin in treating bacteria in the blood in patients with neutropenia caused by chemotherapy. PURPOSE: This randomized clinical trial is studying daptomycin to see how well it works compared with vancomycin in treating bacteria in the blood in patients with neutropenia caused by chemotherapy.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Infection | — | UNRESOLVED | — |
| Neutropenia | — | UNRESOLVED | — |
| Unspecified Adult Solid Tumor, Protocol Specific | Adult Solid Neoplasm | ALIAS | 0.85 |
| Unspecified Childhood Solid Tumor, Protocol Specific | Childhood Solid Neoplasm | ALIAS | 0.85 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| daptomycin | Drug | — | UNRESOLVED |
| vancomycin | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- vancomycin
- interventionNames
- Drug: vancomycin
- type
- EXPERIMENTAL
- label
- daptomycin
- interventionNames
- Drug: daptomycin
Primary outcomes (2)
- measure
- determine the efficacy of daptomycin to treat gram positive infections
- timeFrame
- day 7
- measure
- determine the safety of daptomycin in neutropenic patients
- timeFrame
- day 7
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 120 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Diagnosis of a malignancy * Chemotherapy-induced neutropenia (absolute neutrophil count \< 500/mm\^3) * Two or more blood cultures positive for gram-positive cocci * At least 0.2 colony-forming units/mL on lysis-centrifugation culture * Currently receiving broad-spectrum antimicrobial therapy appropriate for febrile neutropenia * No meningitis, endocarditis, osteomyelitis, or pneumonia (by clinical or radiologic criteria) PATIENT CHARACTERISTICS: * Life expectancy ≥ 7 days * No allergy or intolerance to vancomycin or daptomycin * Creatinine clearance ≥ 30 mL/min * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception during and for at least 30 days after completion of study treatment * No underlying myopathy or neurologic disease (e.g., Guillan-Barre or multiple sclerosis) PRIOR CONCURRENT THERAPY: * See Disease Characteristics * No concurrent HMG CoA reductase inhibitors (statins) * No concurrent gemfibrozil or clofibrate
References
Publications (0)
Data not yet available